Arrakis Therapeutics
Small molecule drugs that target RNA secondary structures to enable treatment of previously undruggable disease targets
- Sector
- Biotech
- Headquarters
- Waltham, MA
- Founded
- 2015
- Latest Form D
- $15M, Apr 2019
- Total capital
- $28.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $28.2M
- 2 Form D · last Apr 2019
- 90 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 38 pending · first 2023
- Rank in peer group#397 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$15M
- Private capital raisedForm D · SEC · 1st filing$13.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#397 · top 27%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alan E. WaltsDirectorNamed in SEC Form D filings
- Carolyn E. GreenDirectorNamed in SEC Form D filings
- Colleen E. CuffaroDirectorNamed in SEC Form D filings
- David E. NeafusExecutive OfficerNamed in SEC Form D filings
- Jakob LovenDirectorNamed in SEC Form D filings
- Michael GilmanExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
- Nikola TrbovicDirectorNamed in SEC Form D filings
- Raj ParekhDirectorNamed in SEC Form D filings
- Richard GasterDirectorNamed in SEC Form D filings
- Russell C. PetterExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 40- GrantedNucleic Acid-binding Photoprobes And Uses ThereofUSPTOUS 12,503,455
- PendingRna Degraders And Uses ThereofUSPTOApplication 18705376
- GrantedNucleic Acid-binding Photoprobes And Uses ThereofUSPTOUS 11,807,623
Show all 40 patent records
- Nucleic Acid-binding Photoprobes And Uses ThereofDec 23, 2025 · US 12,503,455Granted
- Rna Degraders And Uses ThereofApr 10, 2025 · Application 18705376Pending
- Nucleic Acid-binding Photoprobes And Uses ThereofNov 7, 2023 · US 11,807,623Granted
- Compounds And Methods For Modulating Rna FunctionDec 22, 2022 · Application 17805634Pending
- Compounds And Methods Of Treating Rna-mediated DiseasesSep 8, 2022 · Application 17644986Pending
- Compounds And Methods Of Treating Rna-mediated DiseasesApr 16, 2020 · Application 16074232Pending
- Compounds And Methods For Modulating Rna FunctionJun 27, 2019 · Application 16314127Pending
- Compositions And Methods For Treating Myc-mediated DiseasesApplication PCTUS2024061415Pending
- Quinazoline Compounds And Methods Of Use Thereof For Treating Myc-mediated DiseasesApplication PCTUS2024061464Pending
- Compositions And Methods Of Use Thereof For Treating Myc-mediated DiseasesApplication PCTUS2024061428Pending
- Isoquinoline TCF4 BindersApplication 63715976Pending
- Isoquinoline Dmpk BindersApplication 63715961Pending
- CNOT9 Binding Rna DegradersApplication 63700384Pending
- CCR4-NOT Binding Rna DegradersApplication PCTUS2024039375Pending
- Quinazoline Compounds And Methods Of Use Thereof For Treating Myc-mediated DiseasesApplication 63659584Pending
- CCR4-NOT Binding Rna DegradersApplication 63655954Pending
- Covalent Inhibitors And Uses ThereofApplication 63558555Pending
- Compositions And Methods For Treating Myc-mediated DiseasesApplication 63614274Pending
- Compositions And Methods Of Use Thereof For Treating Myc-mediated DiseasesApplication 63614318Pending
- Quinazoline Compounds And Methods Of Use Thereof For Treating Myc-mediated DiseasesApplication 63614299Pending
- Rna Degraders And Uses ThereofApplication PCTUS2023080959Pending
- Rna Degraders And Uses ThereofApplication 63589907Pending
- CCR4-NOT Binding Rna DegradersApplication 63589853Pending
- CCR4-NOT Binding Rna DegradersApplication 63515259Pending
- Rna Degraders And Uses ThereofApplication 63499879Pending
- Rna Degraders And Uses ThereofApplication 63489644Pending
- Rna Degraders And Uses ThereofApplication 63384839Pending
- Rna Degraders And Uses ThereofApplication PCTUS2022078892Pending
- Rna Degraders And Uses ThereofApplication 63263208Pending
- Compounds And Methods For Modulating Rna FunctionApplication 17060602Pending
- Encoded Libraries And Methods Of Use For Screening Nucleic Acid TargetsApplication PCTUS2019035481Pending
- Nucleic Acid-binding Photoprobes And Uses ThereofApplication PCTUS2018063490Pending
- Encoded Libraries And Methods Of Use For Screening Nucleic Acid TargetsApplication 62680946Pending
- Nucleic Acid-binding Photoprobes And Uses ThereofApplication 62593175Pending
- Compounds And Methods For Modulating Rna FunctionApplication PCTUS2017040514Pending
- Compounds And Methods Of Treating Rna-mediated DiseasesApplication PCTUS2017016065Pending
- Compounds And Methods For Modulating Rna FunctionApplication 62453487Pending
- Compounds And Methods For Modulating Rna FunctionApplication 62357654Pending
- Methods Of Treating Rna-mediated DiseasesApplication 62289671Pending
- Covalent Inhibitors And Uses ThereofApplication 19618848Pending
Related companies, and why
- Sift Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- OneSkin, Inc.Similar federal contract value in Biotech · null in contracts
- Xcell Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Abeona Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Prevail TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Carbon BiosciencesSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .